Breaking News Instant updates and real-time market news.

TODAY'S FREE FLY STORIES

Syndicate
Ekso Bionics files to sell 874K shares of common stock for holders  17:25
07/02/20
07/02
17:25
07/02/20
17:25
EKSO

Ekso Bionics

$7.35 /

+0.04 (+0.55%)

 
ShowHide Related Items >><<
EKSO Ekso Bionics
$7.35 /

+0.04 (+0.55%)

EKSO Ekso Bionics
$7.35 /

+0.04 (+0.55%)

06/26/20 H.C. Wainwright
Ekso Bionics price target raised to $12 from $8 at H.C. Wainwright
01/10/20 H.C. Wainwright
Ekso's Q4 pre-announcement 'bodes well' for 2020 growth, says H.C. Wainwright
10/28/19 H.C. Wainwright
Ekso Bionics initiated with a Buy at H.C. Wainwright
09/06/19 Cantor Fitzgerald
Ekso Bionics initiated with an Overweight at Cantor Fitzgerald
EKSO Ekso Bionics
$7.35 /

+0.04 (+0.55%)

EKSO Ekso Bionics
$7.35 /

+0.04 (+0.55%)

Syndicate
Adial Pharmaceuticals files to sell 2.12M shares of common stock for holders  17:24
07/02/20
07/02
17:24
07/02/20
17:24
ADIL

Adial Pharmaceuticals

$1.36 /

-0.05 (-3.55%)

 
ShowHide Related Items >><<
ADIL Adial Pharmaceuticals
$1.36 /

-0.05 (-3.55%)

ADIL Adial Pharmaceuticals
$1.36 /

-0.05 (-3.55%)

Hot Stocks
Medical Properties Trust CFO sells 220K shares of common stock » 17:13
07/02/20
07/02
17:13
07/02/20
17:13
MPW

Medical Properties Trust

$19.03 /

-0.29 (-1.50%)

In a regulatory filing,…

In a regulatory filing, Medical Properties Trust CFO Steven Hamner disclosed the sale of 220,000 common shares of the company at a price of $19.12 per share on July 2nd.

ShowHide Related Items >><<
MPW Medical Properties Trust
$19.03 /

-0.29 (-1.50%)

MPW Medical Properties Trust
$19.03 /

-0.29 (-1.50%)

04/23/20 SunTrust
SunTrust lowers price targets on select healthcare REITS
03/30/20 Mizuho
Medical Properties Trust downgraded to Neutral from Buy at Mizuho
03/30/20 Mizuho
Medical Properties Trust downgraded to Neutral from Buy at Mizuho
03/23/20 BofA
Medical Properties Trust upgraded to Buy from Neutral at BofA
MPW Medical Properties Trust
$19.03 /

-0.29 (-1.50%)

  • 06
    Nov
  • 25
    Jul
  • 16
    Jul
MPW Medical Properties Trust
$19.03 /

-0.29 (-1.50%)

General news
Treasury Market Summary » 17:10
07/02/20
07/02
17:10
07/02/20
17:10

Treasury Market Summary:…

Treasury Market Summary: Wall Street rocketed higher on the much better than expected June nonfarm payroll report, extending already solid overnight gains in the futures. The record 4,800k jump in employment, the net 90k upward revisions to April and May, the drop in the jobless rate to 11.1%, and the pop in the participation rate to 61.5% were all good news for the beleaguered economy and job market. The major indexes surged rallying more than 1%. Some profit taking pared the advances, but rally maintained a lot of steam through the afternoon. The NASDAQ was again the leader as the index penetrated the 10,310 mark before drifting to close 0.5% firmer at 10,207. The Dow hovered either side of 26,000 before finishing with a 0.36% gain at 25,827. The S&amp;P 500 was up 0.45% to 3130. Despite the rally in risk, Treasury yield closed slightly richer, taking a cautious stance (and closing early) into the long July 4 weekend. Along with the jobs report, data included a moderate dip in jobless claims, a widening in the trade deficit, and a bounce in factory orders. View the summary.

Conference/Events
Cyclerion Therapeutics to host conference call » 17:05
07/02/20
07/02
17:05
07/02/20
17:05
CYCN

Cyclerion Therapeutics

$5.86 /

+0.01 (+0.17%)

Management holds a…

Management holds a conference call to discuss IW-6463 pre-clinical and Phase 1 clinical study data on July 9 at 8:15 am. Webcast Link

ShowHide Related Items >><<
CYCN Cyclerion Therapeutics
$5.86 /

+0.01 (+0.17%)

CYCN Cyclerion Therapeutics
$5.86 /

+0.01 (+0.17%)

02/26/20 Spin-Off Research
Cyclerion Therapeutics downgraded to Hold from Buy at Spin-Off Research
08/21/19 Spin-Off Research
Cyclerion Therapeutics upgraded to Buy from Hold at Spin-Off Research
CYCN Cyclerion Therapeutics
$5.86 /

+0.01 (+0.17%)

Syndicate
Sonim files to sell 8.23M shares of common stock for holders  17:05
07/02/20
07/02
17:05
07/02/20
17:05
SONM

Sonim

$0.82 /

+0.023 (+2.87%)

 
ShowHide Related Items >><<
SONM Sonim
$0.82 /

+0.023 (+2.87%)

SONM Sonim
$0.82 /

+0.023 (+2.87%)

03/16/20 Lake Street
Sonim price target lowered to $2 from $3 at Lake Street
10/31/19 Oppenheimer
Sonim downgraded to Perform from Outperform at Oppenheimer
10/31/19 Oppenheimer
Sonim downgraded to Perform from Outperform at Oppenheimer
09/11/19 Oppenheimer
Sonim price target lowered to $6 from $18 at Oppenheimer
SONM Sonim
$0.82 /

+0.023 (+2.87%)

  • 05
    Jun
Syndicate
CEL-SCI files to sell 613,792 shares of common stock for holders  17:04
07/02/20
07/02
17:04
07/02/20
17:04
CVM

CEL-SCI

$13.45 /

-0.9 (-6.27%)

 
ShowHide Related Items >><<
CVM CEL-SCI
$13.45 /

-0.9 (-6.27%)

CVM CEL-SCI
$13.45 /

-0.9 (-6.27%)

05/14/20 H.C. Wainwright
CEL-SCI price target raised to $23 from $18 at H.C. Wainwright
01/13/20 H.C. Wainwright
CEL-SCI initiated with a Buy at H.C. Wainwright
  • 24
    Dec
CVM CEL-SCI
$13.45 /

-0.9 (-6.27%)

CVM CEL-SCI
$13.45 /

-0.9 (-6.27%)

Hot Stocks
Anixa redirects resources to therapeutics, vaccines in high-need patients » 17:02
07/02/20
07/02
17:02
07/02/20
17:02
ANIX

Anixa Biosciences

$3.16 /

+0.19 (+6.40%)

Anixa Biosciences…

Anixa Biosciences announced that it has strategically realigned its business focus and redirected resources to exclusively focus on the development of therapeutics and vaccines in high-need patient populations. As part of this realignment, the company has suspended development of the Cchek liquid biopsy technology. Going forward, Anixa's operations will center entirely on the development and expansion of its therapeutics and vaccine portfolio, which includes a cancer immunotherapy program being developed in partnership with the Moffitt Cancer Center, that uses chimeric endocrine receptor T-cell technology, a novel type of CAR-T. Anixa is also developing a cancer vaccine technology addressing breast cancer with a specific focus on triple negative breast cancer, the most lethal form of the disease, in partnership with the Cleveland Clinic. Anixa will continue drug discovery and development of Covid-19 therapies, in partnership with OntoChem, GmbH. In addition, Anixa will continue to examine emerging therapeutic technologies for further development. "Due to the evolving dynamics of the diagnostics market during this pandemic and projected disruptions in this industry, we see greater opportunity to benefit patients and our shareholders as a therapeutics-directed company," said Amit Kumar, Ph.D., Chief Executive Officer of Anixa. "The pandemic and market forces have made it clear that we need to pivot. Our confidence in the Cchek(TM) technology remains undiminished, but we feel the prudent decision is to suspend work on diagnostics at this time."

ShowHide Related Items >><<
ANIX Anixa Biosciences
$3.16 /

+0.19 (+6.40%)

ANIX Anixa Biosciences
$3.16 /

+0.19 (+6.40%)

12/30/19 B. Riley FBR
Anixa Biosciences price target lowered to $8 from $11.25 at B. Riley FBR
Hot Stocks
Pyxis Tankers discloses continued listing notice from Nasdaq » 17:01
07/02/20
07/02
17:01
07/02/20
17:01
PXS

Pyxis Tankers

$0.79 /

+0.0299 (+3.93%)

Pyxis Tankers announced…

Pyxis Tankers announced that it received a deficiency notice from The NASDAQ Stock Market on June 29, 2020 stating that, for a period of 30 consecutive business days, the company's common shares closed below the minimum bid price of $1.00 per share as required for continued listing on Nasdaq. The notice explained that due to the extraordinary market conditions caused by COVID-19, Nasdaq is providing temporary relief and tolling the compliance period until June 30, 2020. The company has until December 28, 2020 to regain compliance with the Minimum Bid Price Requirement. The company is currently reviewing options to meet the requirements for continued listing on Nasdaq.

ShowHide Related Items >><<
PXS Pyxis Tankers
$0.79 /

+0.0299 (+3.93%)

PXS Pyxis Tankers
$0.79 /

+0.0299 (+3.93%)

10/15/19 Aegis
Pyxis Tankers initiated with a Buy at Aegis
PXS Pyxis Tankers
$0.79 /

+0.0299 (+3.93%)

Hot Stocks
Zynga to acquire Toon Blast developer Peak for $1.85B » 16:57
07/02/20
07/02
16:57
07/02/20
16:57
ZNGA

Zynga

$9.52 /

-0.24 (-2.46%)

Zynga has entered into a…

Zynga has entered into a definitive agreement to acquire Peak, "one of the most globally successful mobile gaming companies, for $1.8B. Peak brings a 100-person strong team and two Forever Franchises, Toon Blast and Toy Blast, that have consistently ranked in the top 10 and top 20 U.S. iPhone grossing games for over two years, respectively. These franchises add significant scale to Zynga's live services and will be an additional driver of margin expansion over the coming years. Peak also enhances Zynga's new game pipeline with additional projects in early development." Founded in 2010 by Sidar Sahin, Peak has developed the beloved game franchises Toon Blast and Toy Blast. Known for their innovation, creativity and exquisite design, Toon Blast and Toy Blast popularized the 'collapse' mechanic within match-3 puzzle games, and have captured a highly engaged global audience base that ranks among the industry's best in player retention. Collectively, Toon Blast and Toy Blast have more than 12 million average mobile DAUs. Peak is expected to grow Zynga's average mobile DAUs by more than 60% while strengthening Zynga's international audience," said the company in a statement earlier. Reference Link

ShowHide Related Items >><<
ZNGA Zynga
$9.52 /

-0.24 (-2.46%)

ZNGA Zynga
$9.52 /

-0.24 (-2.46%)

06/22/20 MKM Partners
Snap's new features impressive, says MKM Partners
06/09/20
Fly Intel: Top five analyst upgrades
06/09/20 Barclays
Barclays upgrades Zynga with Peak seen as share inflection point
06/09/20 Barclays
Zynga upgraded to Overweight from Equal Weight at Barclays
ZNGA Zynga
$9.52 /

-0.24 (-2.46%)

ZNGA Zynga
$9.52 /

-0.24 (-2.46%)

ZNGA Zynga
$9.52 /

-0.24 (-2.46%)

ZNGA Zynga
$9.52 /

-0.24 (-2.46%)

Syndicate
Hercules Capital files to sell 16.5M shares of common stock » 16:54
07/02/20
07/02
16:54
07/02/20
16:54
HTGC

Hercules Capital

$10.41 /

+0.095 (+0.92%)

JMP Securities is…

JMP Securities is manager.

ShowHide Related Items >><<
HTGC Hercules Capital
$10.41 /

+0.095 (+0.92%)

HTGC Hercules Capital
$10.41 /

+0.095 (+0.92%)

06/19/20 Janney Montgomery Scott
Hercules Capital upgraded to Buy at Janney Montgomery Scott
06/19/20 Janney Montgomery Scott
Hercules Capital upgraded to Buy from Neutral at Janney Montgomery Scott
03/31/20 Keefe Bruyette
Hercules Capital upgraded to Outperform from Market Perform at Keefe Bruyette
02/21/20 B. Riley FBR
Hercules Capital price target raised to $17 from $15 at B. Riley FBR
HTGC Hercules Capital
$10.41 /

+0.095 (+0.92%)

Periodicals
Delta issues 2,558 potential layoff notices to pilots, Bloomberg reports  16:48
07/02/20
07/02
16:48
07/02/20
16:48
DAL

Delta Air Lines

$27.71 /

+ (+0.00%)

 
ShowHide Related Items >><<
DAL Delta Air Lines
$27.71 /

+ (+0.00%)

DAL Delta Air Lines
$27.71 /

+ (+0.00%)

06/29/20 Goldman Sachs
Delta Air Lines price target raised to $38 from $33 at Goldman Sachs
06/16/20 Stifel
United loyalty deal raises odds of survival without restructuring, says Stifel
06/10/20 JPMorgan
Delta Air Lines price target lowered to $41 from $45 at JPMorgan
06/05/20 Credit Suisse
American stock reaction to demand commentary 'confounding,' says Credit Suisse
DAL Delta Air Lines
$27.71 /

+ (+0.00%)

DAL Delta Air Lines
$27.71 /

+ (+0.00%)

DAL Delta Air Lines
$27.71 /

+ (+0.00%)

DAL Delta Air Lines
$27.71 /

+ (+0.00%)

Conference/Events
Chembio Diagnostics to host business news update conference call » 16:43
07/02/20
07/02
16:43
07/02/20
16:43
CEMI

Chembio Diagnostics

$4.17 /

+0.89 (+27.13%)

Conference call to…

Conference call to discuss COVID-19 product development plans and preliminary 2Q20 revenue results will be held on July 7 at 8 am. Webcast Link

ShowHide Related Items >><<
CEMI Chembio Diagnostics
$4.17 /

+0.89 (+27.13%)

CEMI Chembio Diagnostics
$4.17 /

+0.89 (+27.13%)

06/17/20
Fly Intel: Top five analyst downgrades
06/17/20 Craig-Hallum
Chembio Diagnostics downgraded to Hold from Buy at Craig-Hallum
06/17/20 Colliers
Chembio Diagnostics downgraded to Neutral from Buy at Colliers
06/17/20 Canaccord
Chembio Diagnostics downgraded to Hold at Canaccord
CEMI Chembio Diagnostics
$4.17 /

+0.89 (+27.13%)

  • 07
    May
CEMI Chembio Diagnostics
$4.17 /

+0.89 (+27.13%)

CEMI Chembio Diagnostics
$4.17 /

+0.89 (+27.13%)

Hot Stocks
Uber appoints Flex CEO Revathi Advaithi to board » 16:40
07/02/20
07/02
16:40
07/02/20
16:40
UBER

Uber

$30.66 /

+0.24 (+0.79%)

, FLEX

Flex

$9.96 /

-0.08 (-0.80%)

On July 1, the Board of…

On July 1, the Board of Uber Technologies (UBER) appointed Revathi Advaithi to as an independent director. Advaithi has been Chief Executive Officer of Flex (FLEX) a manufacturer that delivers technology innovation, supply chain, and manufacturing solutions to diverse industries and end markets, since February 2019. Prior to joining Flex, Ms. Advaithi was President and Chief Operating Officer, Electrical Sector, of Eaton (ETN)

ShowHide Related Items >><<
UBER Uber
$30.66 /

+0.24 (+0.79%)

FLEX Flex
$9.96 /

-0.08 (-0.80%)

UBER Uber
$30.66 /

+0.24 (+0.79%)

07/01/20 BTIG
Uber consensus likely aggressive, says BTIG
06/30/20 SunTrust
Uber shouldn't face regulatory issues if it buys Postmates, says Suntrust
06/25/20 Deutsche Bank
Yandex interest in Uber's minority stake modest positive, says Deutsche Bank
06/16/20 JPMorgan
JPMorgan continues to prefer Facebook, Snap in online advertising
FLEX Flex
$9.96 /

-0.08 (-0.80%)

04/22/20 RBC Capital
Flex initiated with a Sector Perform at RBC Capital
03/11/20 JPMorgan
JPMorgan downgrades TTM Technologies to Neutral, prefers others in space
03/10/20 Citi
Flex price target lowered to $13 from $16 at Citi
02/24/20 Stifel
Stifel expects Amphenol peers to follow company in warning due to coronavirus
UBER Uber
$30.66 /

+0.24 (+0.79%)

FLEX Flex
$9.96 /

-0.08 (-0.80%)

  • 11
    Feb
  • 07
    Nov
  • 06
    Nov
UBER Uber
$30.66 /

+0.24 (+0.79%)

UBER Uber
$30.66 /

+0.24 (+0.79%)

UBER Uber
$30.66 /

+0.24 (+0.79%)

Conference/Events
Semtech participates in a conference call with B. Riley FBR » 16:38
07/02/20
07/02
16:38
07/02/20
16:38
SMTC

Semtech

$52.54 /

+1.5 (+2.94%)

Conference call with…

Conference call with President & CEO Maheswaran and CFO Chukwu will be held on July 8 at 4:15 pm. Webcast Link

ShowHide Related Items >><<
SMTC Semtech
$52.54 /

+1.5 (+2.94%)

SMTC Semtech
$52.54 /

+1.5 (+2.94%)

05/28/20 Needham
Semtech price target raised to $65 from $47 at Needham
05/28/20 Loop Capital
Semtech price target raised to $61 from $46 at Loop Capital
05/28/20 Wells Fargo
Semtech price target raised to $57 from $50 at Wells Fargo
05/28/20 Susquehanna
Semtech price target raised to $50 from $40 at Susquehanna
SMTC Semtech
$52.54 /

+1.5 (+2.94%)

SMTC Semtech
$52.54 /

+1.5 (+2.94%)

General news
Fed Balance Sheet Level data reported » 16:37
07/02/20
07/02
16:37
07/02/20
16:37

Week of 7/1 Fed Balance…

Week of 7/1 Fed Balance Sheet Level at $7.009T

General news
Money Supply M2 Weekly Change data reported » 16:37
07/02/20
07/02
16:37
07/02/20
16:37

Week of 6/22 Money Supply…

Week of 6/22 Money Supply M2 Weekly Change at $100.2B

Syndicate
Atreca files $300M mixed securities shelf  16:35
07/02/20
07/02
16:35
07/02/20
16:35
BCEL

Atreca

$22.70 /

+0.57 (+2.58%)

 
ShowHide Related Items >><<
BCEL Atreca
$22.70 /

+0.57 (+2.58%)

BCEL Atreca
$22.70 /

+0.57 (+2.58%)

07/01/20 Canaccord
Atreca price target raised to $33 from $23 at Canaccord
06/10/20 H.C. Wainwright
H.C. Wainwright says Genmab/AbbVie pact a 'big win' for companies like Atreca
04/22/20 H.C. Wainwright
Atreca initiated with a Buy at H.C. Wainwright
04/21/20 Wedbush
Atreca initiated with an Outperform at Wedbush
BCEL Atreca
$22.70 /

+0.57 (+2.58%)

Hot Stocks
ReTo Eco-Solutions receives noncompliance notice from Nasdaq » 16:34
07/02/20
07/02
16:34
07/02/20
16:34
RETO

ReTo Eco-Solutions

$1.26 /

+0.03 (+2.44%)

ReTo Eco-Solutions…

ReTo Eco-Solutions announced it has received a notice from Nasdaq stating that, as a result of not having timely filed its annual report on Form 20-F for the year ended December 31, 2019, ReTo is not in compliance with Nasdaq Listing Rule 5250, which requires timely filing of periodic financial reports with the SEC. The notification has no immediate effect on the listing of the company's common shares, which trade on Nasdaq. ReTo is required by Nasdaq to submit its plan to regain compliance no later than August 31. If the plan is accepted by Nasdaq, ReTo can be granted up to 180 calendar days from the Form 20-F's due date, or until December 28 to regain compliance.

ShowHide Related Items >><<
RETO ReTo Eco-Solutions
$1.26 /

+0.03 (+2.44%)

Hot Stocks
Regeneron falls 3.5% after ph.3 data on Kevzara in Covid patients  16:33
07/02/20
07/02
16:33
07/02/20
16:33
REGN

Regeneron

$622.75 /

+13.53 (+2.22%)

 
ShowHide Related Items >><<
REGN Regeneron
$622.75 /

+13.53 (+2.22%)

REGN Regeneron
$622.75 /

+13.53 (+2.22%)

07/01/20 Oppenheimer
Regeneron price target raised to $675 from $625 at Oppenheimer
06/24/20 Credit Suisse
Regeneron price target raised to $700 from $605 at Credit Suisse
06/24/20 Morgan Stanley
Novartis' syringe suit not a material threat to Regeneron, says Morgan Stanley
06/18/20 Piper Sandler
AbbVie atopic dermatitis data a postive, says Piper Sandler
REGN Regeneron
$622.75 /

+13.53 (+2.22%)

  • 27
    May
REGN Regeneron
$622.75 /

+13.53 (+2.22%)

REGN Regeneron
$622.75 /

+13.53 (+2.22%)

REGN Regeneron
$622.75 /

+13.53 (+2.22%)

On The Fly
Fly Intel: Wall Street's top stories for Thursday » 16:32
07/02/20
07/02
16:32
07/02/20
16:32
TSLA

Tesla

$1,208.00 /

+88.84 (+7.94%)

, F

Ford

$6.05 /

+0.065 (+1.09%)

, MCD

McDonald's

$183.55 /

-0.95 (-0.51%)

, LMND

Lemonade

$69.38 /

+ (+0.00%)

, MRNA

Moderna

$58.57 /

-3.06 (-4.97%)

, GRAF

Graf Industrial

$20.56 /

+6.605 (+47.33%)

, NUS

Nu Skin

$48.09 /

+9.605 (+24.96%)

, MEIP

MEI Pharma

$3.48 /

-0.79 (-18.50%)

, MTCH

Match Group

$98.89 /

-7.35 (-6.92%)

Stocks closed out the…

Open Full Text

ShowHide Related Items >><<
TSLA Tesla
$1,208.00 /

+88.84 (+7.94%)

NUS Nu Skin
$48.09 /

+9.605 (+24.96%)

MTCH Match Group
$98.89 /

-7.35 (-6.92%)

MRNA Moderna
$58.57 /

-3.06 (-4.97%)

MEIP MEI Pharma
$3.48 /

-0.79 (-18.50%)

MCD McDonald's
$183.55 /

-0.95 (-0.51%)

GRAF Graf Industrial
$20.56 /

+6.605 (+47.33%)

F Ford
$6.05 /

+0.065 (+1.09%)

TSLA Tesla
$1,208.00 /

+88.84 (+7.94%)

07/02/20 Wedbush
Wedbush boosts Tesla target to $1,250 with new bull case of $2,000
07/01/20 Wedbush
'Impressive' trajectory in June bodes well for Tesla deliveries, says Wedbush
06/30/20 Oppenheimer
Oppenheimer anticipates in-line or ahead of consensus Q2 deliveries for Tesla
06/30/20 JMP Securities
Tesla price target raised to $1,050 from $1,001 at JMP Securities
F Ford
$6.05 /

+0.065 (+1.09%)

06/25/20 Morgan Stanley
Talks with Ford dealer highlight inventory risk, says Morgan Stanley
06/24/20 Morgan Stanley
GM electric vehicle business could be worth $100B, says Morgan Stanley
06/19/20 JPMorgan
Ford price target raised to $7 from $6 at JPMorgan
06/18/20 Jefferies
Jefferies raises price targets for Ford, GM and FCA on balance sheet de-risking
MCD McDonald's
$183.55 /

-0.95 (-0.51%)

06/24/20 BMO Capital
McDonald's price target raised to $220 from $215 at BMO Capital
06/24/20 JPMorgan
McDonald's price target raised to $204 from $180 at JPMorgan
06/17/20 Morgan Stanley
McDonald's price target raised to $200 from $189 at Morgan Stanley
06/17/20 SunTrust
McDonald's price target raised to $208 from $195 at SunTrust
LMND Lemonade
$69.38 /

+ (+0.00%)

MRNA Moderna
$58.57 /

-3.06 (-4.97%)

07/02/20 BMO Capital
Moderna mRNA platform supported by Pfizer vaccine data, says BMO Capital
06/30/20 Argus
Moderna initiated with a Buy at Argus
06/30/20 Argus
Moderna initiated with a Buy at Argus
06/26/20 Morgan Stanley
Morgan Stanley says Axios overstates contention on Moderna-NIH vaccine ownership
GRAF Graf Industrial
$20.56 /

+6.605 (+47.33%)

NUS Nu Skin
$48.09 /

+9.605 (+24.96%)

07/02/20
Fly Intel: Top five analyst upgrades
07/02/20 DA Davidson
Nu Skin upgraded to Buy from Neutral at DA Davidson
07/02/20 DA Davidson
Nu Skin upgraded to Buy from Neutral at DA Davidson
07/02/20 Jefferies
Jefferies upgrades Nu Skin to Buy, sees 15%-20% share upside
MEIP MEI Pharma
$3.48 /

-0.79 (-18.50%)

05/29/20
Fly Intel: Top five analyst initiations
05/29/20 SunTrust
MEI Pharma initiated with a Buy at SunTrust
04/14/20 JonesTrading
MEI Pharma price target raised to $9 from $6 at JonesTrading
04/14/20 Wells Fargo
MEI Pharma price target raised to $13 from $11 at Wells Fargo
MTCH Match Group
$98.89 /

-7.35 (-6.92%)

07/02/20 BTIG
IAC price target lowered to $150 from $330 at BTIG
06/23/20 SunTrust
SunTrust raises price targets on IAC, Angi Homeservices, Match Group
06/23/20 BMO Capital
Angi Homeservices price target raised to $16 from $10 at BMO Capital
06/23/20 BMO Capital
IAC price target raised to $369 from $316 at BMO Capital
TSLA Tesla
$1,208.00 /

+88.84 (+7.94%)

NUS Nu Skin
$48.09 /

+9.605 (+24.96%)

MTCH Match Group
$98.89 /

-7.35 (-6.92%)

MRNA Moderna
$58.57 /

-3.06 (-4.97%)

MEIP MEI Pharma
$3.48 /

-0.79 (-18.50%)

MCD McDonald's
$183.55 /

-0.95 (-0.51%)

F Ford
$6.05 /

+0.065 (+1.09%)

  • 02
    Jul
  • 19
    May
  • 14
    Feb
  • 12
    Feb
  • 17
    Dec
TSLA Tesla
$1,208.00 /

+88.84 (+7.94%)

MTCH Match Group
$98.89 /

-7.35 (-6.92%)

MRNA Moderna
$58.57 /

-3.06 (-4.97%)

MCD McDonald's
$183.55 /

-0.95 (-0.51%)

GRAF Graf Industrial
$20.56 /

+6.605 (+47.33%)

F Ford
$6.05 /

+0.065 (+1.09%)

TSLA Tesla
$1,208.00 /

+88.84 (+7.94%)

MTCH Match Group
$98.89 /

-7.35 (-6.92%)

MRNA Moderna
$58.57 /

-3.06 (-4.97%)

MEIP MEI Pharma
$3.48 /

-0.79 (-18.50%)

MCD McDonald's
$183.55 /

-0.95 (-0.51%)

F Ford
$6.05 /

+0.065 (+1.09%)

TSLA Tesla
$1,208.00 /

+88.84 (+7.94%)

MTCH Match Group
$98.89 /

-7.35 (-6.92%)

MRNA Moderna
$58.57 /

-3.06 (-4.97%)

MEIP MEI Pharma
$3.48 /

-0.79 (-18.50%)

MCD McDonald's
$183.55 /

-0.95 (-0.51%)

F Ford
$6.05 /

+0.065 (+1.09%)

TSLA Tesla
$1,208.00 /

+88.84 (+7.94%)

Hot Stocks
Regeneron/Sanofi's ph3 trial of Kevzara in COVID did not meet endpoints » 16:32
07/02/20
07/02
16:32
07/02/20
16:32
SNY

Sanofi

$51.65 /

+0.37 (+0.72%)

, REGN

Regeneron

$622.75 /

+13.53 (+2.22%)

Regeneron (REGN) and…

Regeneron (REGN) and Sanofi (SNY) announced that the U.S. Phase 3 trial of Kevzara or sarilumab, 400 mg in COVID-19 patients requiring mechanical ventilation did not meet its primary and key secondary endpoints when Kevzara was added to best supportive care compared to best supportive care alone. Minor positive trends were observed in the primary pre-specified analysis group that did not reach statistical significance, and these were countered by negative trends in a subgroup of critical patients who were not mechanically ventilated at baseline. In the primary analysis group, adverse events were experienced by 80% of Kevzara patients and 77% of placebo patients. Serious adverse events that occurred in at least 3% of patients and more frequently among Kevzara patients were multi-organ dysfunction syndrome and hypotension. Based on the results, the U.S.-based trial has been stopped, including in a second cohort of patients who received a higher dose of Kevzara of 800 mg.

ShowHide Related Items >><<
SNY Sanofi
$51.65 /

+0.37 (+0.72%)

REGN Regeneron
$622.75 /

+13.53 (+2.22%)

SNY Sanofi
$51.65 /

+0.37 (+0.72%)

07/01/20 Roth Capital
Applied Genetic may attract Sanofi takeover interest, says Roth Capital
06/26/20 SunTrust
Translate Bio initiated with a Buy at SunTrust
06/24/20 Roth Capital
Translate Bio price target raised to $30 from $25 at Roth Capital
06/23/20 Jefferies
Translate Bio price target raised to $29 from $17 at Jefferies
REGN Regeneron
$622.75 /

+13.53 (+2.22%)

07/01/20 Oppenheimer
Regeneron price target raised to $675 from $625 at Oppenheimer
06/24/20 Credit Suisse
Regeneron price target raised to $700 from $605 at Credit Suisse
06/24/20 Morgan Stanley
Novartis' syringe suit not a material threat to Regeneron, says Morgan Stanley
06/18/20 Piper Sandler
AbbVie atopic dermatitis data a postive, says Piper Sandler
SNY Sanofi
$51.65 /

+0.37 (+0.72%)

REGN Regeneron
$622.75 /

+13.53 (+2.22%)

  • 27
    May
SNY Sanofi
$51.65 /

+0.37 (+0.72%)

REGN Regeneron
$622.75 /

+13.53 (+2.22%)

SNY Sanofi
$51.65 /

+0.37 (+0.72%)

REGN Regeneron
$622.75 /

+13.53 (+2.22%)

SNY Sanofi
$51.65 /

+0.37 (+0.72%)

REGN Regeneron
$622.75 /

+13.53 (+2.22%)

Syndicate
Personalis files to sell 11.53M shares of common stock for holders  16:31
07/02/20
07/02
16:31
07/02/20
16:31
PSNL

Personalis

$14.24 /

+0.51 (+3.71%)

 
ShowHide Related Items >><<
PSNL Personalis
$14.24 /

+0.51 (+3.71%)

PSNL Personalis
$14.24 /

+0.51 (+3.71%)

11/14/19 Oppenheimer
Personalis price target lowered to $26 from $29 at Oppenheimer
09/26/19 BofA
Bruker, PerkinElmer, Personalis upgraded to Buy at BofA/Merrill
09/26/19 BofA
Personalis upgraded to Buy from Neutral at BofA/Merrill
07/15/19 Cowen
Personalis initiated with an Outperform at Cowen
PSNL Personalis
$14.24 /

+0.51 (+3.71%)

PSNL Personalis
$14.24 /

+0.51 (+3.71%)

Hot Stocks
Clear Channel Outdoor regains compliance with NYSE minimum price standard » 16:31
07/02/20
07/02
16:31
07/02/20
16:31
CCO

Clear Channel Outdoor

$1.04 /

+ (+0.00%)

Clear Channel Outdoor…

Clear Channel Outdoor Holdings announced that on July 1, 2020, the company was notified by the New York Stock Exchange that it has regained compliance with the NYSE's continued listing standards. As previously disclosed, on April 10, 2020, Clear Channel Outdoor received formal notice from the NYSE that it was not in compliance with the NYSE's continued listing standards as a result of the average closing price of the company's common stock being less than $1.00 per share over a consecutive 30 trading-day period. Clear Channel Outdoor regained compliance after its average closing price for the 30 trading days ended June 30, 2020, exceeded the NYSE's minimum requirement of $1.00 based on a 30 trading-day average.

ShowHide Related Items >><<
CCO Clear Channel Outdoor
$1.04 /

+ (+0.00%)

CCO Clear Channel Outdoor
$1.04 /

+ (+0.00%)

06/24/20
Fly Intel: Top five analyst upgrades
06/24/20 Citi
Clear Channel Outdoor upgraded to Buy from Neutral at Citi
06/16/20 Cowen
Clear Channel Outdoor price target raised to $2.20 from $1.50 at Cowen
04/01/20 Barrington
Clear Channel Outdoor downgraded to Market Perform from Outperform at Barrington
CCO Clear Channel Outdoor
$1.04 /

+ (+0.00%)

  • 26
    Jul
CCO Clear Channel Outdoor
$1.04 /

+ (+0.00%)

Syndicate
Hancock Jaffe Laboratories files to sell common stock, warrants  16:31
07/02/20
07/02
16:31
07/02/20
16:31
HJLI

Hancock Jaffe Laboratories

$0.41 /

+0.0268 (+6.96%)

 
ShowHide Related Items >><<
HJLI Hancock Jaffe Laboratories
$0.41 /

+0.0268 (+6.96%)

HJLI Hancock Jaffe Laboratories
$0.41 /

+0.0268 (+6.96%)

08/06/19 Maxim
Hancock Jaffe Laboratories initiated with a Buy at Maxim
08/06/19 Maxim
Hancock Jaffe Laboratories initiated with a Buy at Maxim

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.